Answers are grounded in this paper and cite their sources.
Asprosin, a fasting-induced adipokine derived from the C-terminal cleavage of profibrillin-1, modulates glucose homeostasis and appetite and participates in multiple physiological and pathophysiological processes. White adipose tissue is the main source of circulating asprosin, although pancreatic beta (β)-cells, salivary glands, and cartilage also produce it. Asprosin stimulates hepatic glucose release via olfactory receptor (OLFR734)-dependent G protein–cAMP–PKA signaling and promotes feeding by activating hypothalamic Agouti-related peptide (AgRP) neurons; dysregulated asprosin levels associate with obesity, insulin resistance, type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease (NAFLD), and reproductive and cardiovascular disorders. This narrative review summarizes the discovery, sources, signaling mechanisms, systemic effects (endocrine/metabolic, gastrointestinal, nervous, cardiovascular, respiratory, reproductive, renal, musculoskeletal), and therapeutic implications of asprosin, and highlights areas where further research is needed.
No takes yet. Share an insight, caveat, or question.
Maru et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: